How should Nystatin be dosed and administered for a 4‑month‑old infant with oral candidiasis?

Nystatin for Oral Candidiasis in a 4-Month-Old Infant

For a 4-month-old infant with oral candidiasis, administer nystatin oral suspension 1 mL (100,000 units) four times daily for 7–14 days, placing one-half of the dose (0.5 mL) in each side of the mouth using a dropper and avoiding feeding for 5–10 minutes after administration. 1

Standard Dosing Regimen

• The FDA-approved dosing for infants is 2 mL (200,000 units) four times daily, with one-half of the dose placed in each side of the mouth using a dropper, avoiding feeding for 5–10 minutes after administration. 1

• However, limited clinical studies in premature and low birth weight infants indicate that 1 mL (100,000 units) four times daily is effective, making this an acceptable alternative for smaller or younger infants. 1

• The American Academy of Pediatrics recommends nystatin suspension (100,000 IU/mL): 1 mL four times daily for 7–14 days as first-line treatment for oral candidiasis in infants. 2

Treatment Duration and Endpoint

• Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans. 1

• The standard treatment duration is 7–14 days, with most guidelines recommending continuation until at least 48 hours after complete symptom resolution to reduce relapse risk. 2, 3

Administration Technique

• Use a dropper to place one-half of the dose (0.5 mL or 1 mL depending on total dose) in each side of the mouth. 1

• Avoid feeding for 5–10 minutes after administration to maximize contact time with oral mucosa. 1

• The medication should be retained in the mouth as long as possible before swallowing to ensure adequate mucosal contact. 1

When to Consider Systemic Fluconazole Instead

Fluconazole is significantly superior to nystatin and should be considered as first-line therapy in the following situations:

• Moderate-to-severe disease with extensive lesions or posterior pharyngeal involvement requires systemic fluconazole 3–6 mg/kg once daily for 7 days. 2, 4

• Immunocompromised infants (including premature infants with disseminated disease or those at risk for invasive candidiasis) require systemic therapy, not topical nystatin. 2

• Treatment failure after 7–14 days of nystatin warrants switching to fluconazole 3–6 mg/kg once daily for 7 days, which achieves clinical cure rates of 91–100% versus only 32–54% with nystatin. 4, 5

• A randomized trial in infants demonstrated that fluconazole achieved 100% clinical cure (15/15 patients) compared to only 32% with nystatin (6/19 patients), p < 0.0001. 5

Critical Pitfalls to Avoid

• Do not use nystatin for suspected esophageal involvement, even without dysphagia, as topical agents cannot penetrate esophageal tissue; systemic fluconazole is mandatory. 2, 4

• Premature infants should be monitored for potential adverse effects including intestinal damage and necrotizing enterocolitis, which have been associated with nystatin prophylaxis. 6, 2

• The most common cause of apparent "resistance" is premature discontinuation when symptoms improve but before mycological cure is achieved; always complete the full 7–14 day course. 4

• Avoid repeating nystatin courses after early recurrence; this indicates treatment failure and warrants switching to fluconazole rather than repeating an ineffective regimen. 4

Special Considerations for Breastfeeding-Associated Thrush

• When oral candidiasis is associated with breastfeeding, simultaneous treatment of both mother and infant is recommended, with the mother applying miconazole cream to nipples/areola after each feeding. 2

Safety Profile

• Nystatin is generally well-tolerated in infants, with poor taste and gastrointestinal adverse reactions being the most common side effects. 7

• No long-term carcinogenicity or mutagenicity studies have been performed, but extensive clinical use supports its safety profile in infants. 1

• Discontinue treatment if sensitization or irritation occurs during use. 1

Prophylaxis in High-Risk Neonates

• In neonatal intensive care units with invasive candidiasis rates >10%, fluconazole prophylaxis 3–6 mg/kg twice weekly for 6 weeks is recommended for infants <1000g birth weight, not routine nystatin prophylaxis. 6, 2

• Oral nystatin 100,000 IU three times daily for 6 weeks is an alternative prophylactic regimen when fluconazole is unavailable or resistance is a concern, though it reduces fungal infection without changing mortality and carries potential risk of necrotizing enterocolitis. 6, 2